Immunotherapy for Breast Cancer Using Sialyl-Tn
Author Information
Author(s): DW Miles, KE Towlson, R Graham, M Reddish, BM Longenecker, J Taylor-Papadimitriou, RD Rubens
Primary Institution: ICRF Clinical Oncology Unit, Guy's Hospital
Hypothesis
Does low-dose cyclophosphamide pretreatment enhance the immune response to sialyl-Tn-KLH with DETOX-B in patients with metastatic breast cancer?
Conclusion
The study found that low-dose cyclophosphamide can augment the immune response to sialyl-Tn in breast cancer patients, although measurable tumor responses were limited.
Supporting Evidence
- All patients developed IgG and IgM responses to sialyl-Tn.
- Two minor responses were noted in patients who received the active specific immunotherapy injections.
- Levels of IgM antibodies were significantly higher in patients pretreated with cyclophosphamide.
Takeaway
Doctors tested a new treatment for breast cancer that uses a special vaccine and a medicine to help the immune system work better. They found that it helped some patients, but not everyone.
Methodology
Patients with metastatic breast cancer were randomized to receive a vaccine with or without cyclophosphamide pretreatment, and their immune responses and tumor responses were assessed.
Limitations
The study had a small sample size and limited measurable tumor responses.
Participant Demographics
Median age was 56 years, with a range of 36-73 years; most had prior treatments for metastatic disease.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website